{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T23:55:37Z","timestamp":1788134137346,"version":"build-2803163510"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/yco.0b013e32832a16da","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T07:14:53Z","timestamp":1242890093000},"page":"293-299","source":"Crossref","is-referenced-by-count":74,"title":["Akathisia and second-generation antipsychotic drugs"],"prefix":"10.1097","volume":"22","author":[{"given":"Rajeev","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perminder S","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210206","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.psc.2004.10.004","article-title":"Neuroleptic-induced movement disorders: an overview","volume":"28","author":"Sachdev","year":"2005","journal-title":"Psychiatr Clin N Am"},{"key":"R2-9-20210206","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/026988119701100301","article-title":"What is an atypical antipsychotic?","volume":"11","author":"Reynolds","year":"1997","journal-title":"J Psychopharmacol"},{"key":"R3-9-20210206","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10673220600748486","article-title":"Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome","volume":"14","author":"Shirzadi","year":"2006","journal-title":"Harv Rev Psychiatry"},{"key":"R4-9-20210206","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1600-0447.2008.01206.x","article-title":"Antipsychotic-induced movement disorders \u2013 forgotten but not gone","volume":"117","author":"Weiden","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"R5-9-20210206","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archpsyc.1985.01790320042006","article-title":"Akathisia variants and tardive dyskinesia","volume":"42","author":"Barnes","year":"1985","journal-title":"Arch Gen Psychiatry"},{"key":"R6-9-20210206","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511530203","article-title":"Akathisia and restless legs","author":"Sachdev","year":"1995"},{"key":"R7-9-20210206","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00005053-199107000-00001","article-title":"The present status of akathisia","volume":"179","author":"Sachdev","year":"1991","journal-title":"J Nerv Ment Dis"},{"key":"R8-9-20210206","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archpsyc.1994.03950120035007","article-title":"Clinical characteristics and risk factors for acute neuroleptic-induced akathisia","volume":"51","author":"Sachdev","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"R9-9-20210206","first-page":"1","article-title":"A systematic review of atypical antipsychotic drugs in schizophrenia","volume":"6","author":"Bagnall","year":"2003","journal-title":"Health Technol Assess"},{"key":"R10-9-20210206","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"R12-9-20210206","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00004714-198712000-00002","article-title":"The risks and benefits of clozapine versus chlorpromazine","volume":"7","author":"Claghorn","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"R13-9-20210206","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0006-3223(91)90329-K","article-title":"Prevalence and severity of akathisia in patients on clozapine","volume":"29","author":"Cohen","year":"1991","journal-title":"Biol Psychiatry"},{"key":"R14-9-20210206","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.jcp.0000248618.49789.55","article-title":"Acute nocturnal akathisia induced by clozapine","volume":"27","author":"Sahoo","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R17-9-20210206","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00406-006-0643-9","article-title":"Risperidone augmentation of clozapine: a critical review","volume":"256","author":"Kontaxakis","year":"2006","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R18-9-20210206","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/JCP.0b013e3180ca83b1","article-title":"Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa","volume":"27","author":"Dossenbach","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R19-9-20210206","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jad.2007.05.009","article-title":"Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Observational study","volume":"106","author":"Vieta","year":"2008","journal-title":"J Affect Disord"},{"key":"R20-9-20210206","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1399-5618.2006.00350.x","article-title":"Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania","volume":"8","author":"Nasrallah","year":"2006","journal-title":"Bipolar Disord"},{"key":"R21-9-20210206","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/jcp.0b013e318160864f","article-title":"Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia","volume":"28","author":"Cortese","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R22-9-20210206","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","article-title":"Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia","volume":"28","author":"Cutler","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R23-9-20210206","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1176\/appi.ajp.163.3.546","article-title":"Sudden akathisia after a ziprasidone dose reduction","volume":"163","author":"Oral","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R24-9-20210206","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v68n0604","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study","volume":"68","author":"Berman","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R26-9-20210206","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4088\/PCC.v08n0205","article-title":"An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression","volume":"8","author":"Patkar","year":"2006","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"R27-9-20210206","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.pnpbp.2006.12.009","article-title":"Aripiprazole augmentation in treatment resistant bipolar depression: early response and development of akathisia","volume":"31","author":"Kemp","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R28-9-20210206","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000100779","article-title":"Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomized, open, prospective study","volume":"54","author":"Lim","year":"2006","journal-title":"Neuropsychobiology"},{"key":"R29-9-20210206","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/08039480701226146","article-title":"On the relationship of atypical and low-dose conventional antipsychotics with akathisia in a clinical patient population","volume":"61","author":"Markkula","year":"2007","journal-title":"Nord J Psychiatry"},{"key":"R30-9-20210206","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R31-9-20210206","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of antipsychotics in a randomized trial","volume":"193","author":"Miller","year":"2008","journal-title":"Br J Psychiatry"},{"key":"R32-9-20210206","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the treatment of early onset schizophrenia spectrum disorders (TEOSS) study","volume":"165","author":"Sikich","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R33-9-20210206","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pnpbp.2005.10.014","article-title":"Extrapyramidal side effects with atypical neuroleptics in bipolar disorder","volume":"30","author":"Ghaemi","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R34-9-20210206","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2007.10.018","article-title":"Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment","volume":"100","author":"Modestin","year":"2008","journal-title":"Schizophr Res"},{"key":"R35-9-20210206","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/JCP.0b013e318166c4d5","article-title":"Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review","volume":"28","author":"Gao","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R36-9-20210206","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/pgmj.2007.062117","article-title":"Neuropsychiatric complications of commonly used palliative care drugs","volume":"84","author":"Jackson","year":"2008","journal-title":"Postgrad Med J"},{"key":"R37-9-20210206","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1600-0447.2008.01183.x","article-title":"Acculturation is associated with the prevalence of tardive dyskinesia and akathisia in community treated patients with schizophrenia","volume":"117","author":"Sundram","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"R38-9-20210206","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.schres.2006.05.009","article-title":"Does smoking reduce akathisia? Testing a narrow version of the self-medication hypothesis","volume":"86","author":"de Leon","year":"2006","journal-title":"Schizophr Res"},{"key":"R39-9-20210206","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/jnnp.2005.079228","article-title":"Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder","volume":"77","author":"Potvin","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R40-9-20210206","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2710.2007.00848.x","article-title":"Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol","volume":"32","author":"Kim","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"R41-9-20210206","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/0269881107081530","article-title":"Akathisia \u2013 seen from the patients' perspective","volume":"22","author":"Hansen","year":"2008","journal-title":"J Psychopharmacol"},{"key":"R42-9-20210206","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1192\/bjp.188.2.192","article-title":"Akathisia as a risk factor for suicide","volume":"188","author":"Hansen","year":"2006","journal-title":"Br J Psychiatry"},{"key":"R43-9-20210206","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1176\/appi.ajp.2007.07071150","article-title":"Chronic restlessness with antipsychotics","volume":"164","author":"Bratti","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R44-9-20210206","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00787-007-0633-0","article-title":"Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia","volume":"17","author":"Gebhardt","year":"2008","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"R45-9-20210206","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/cap.2006.16.393","article-title":"An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia","volume":"16","author":"Mozes","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R46-9-20210206","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.euroneuro.2006.07.001","article-title":"Striatal D (2) receptor occupancy in bipolar patients treated with olanzapine","volume":"17","author":"Attarbaschi","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"R47-9-20210206","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.07.012","article-title":"Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia \u2013findings from an in vivo SPECT study","volume":"88","author":"Voruganti","year":"2006","journal-title":"Schizophr Res"},{"key":"R48-9-20210206","first-page":"737","article-title":"Cerebellar and thalamic metabolic changes visualized by [18]-FDG-PET in olanzapine-induced acute akathisia","volume":"27","author":"Landgrebe","year":"2006","journal-title":"Neuro Endocrinol Lett"},{"key":"R49-9-20210206","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.pnpbp.2008.05.022","article-title":"Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes","volume":"32","author":"Dolzan","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R51-9-20210206","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.annemergmed.2008.08.003","article-title":"A randomized trial of diphenhydramine as prophylaxis against metoclopramide-induced akathisia in nauseated emergency department patients","volume":"53","author":"Friedman","year":"2009","journal-title":"Ann Emerg Med"},{"key":"R52-9-20210206","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1345\/aph.1K672","article-title":"Role of mirtazapine in the treatment of antipsychotic-induced akathisia","volume":"42","author":"Hieber","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R53-9-20210206","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.biopsych.2005.12.007","article-title":"Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial","volume":"59","author":"Poyurovsky","year":"2006","journal-title":"Biol Psychiatry"},{"key":"R54-9-20210206","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/jcp.0b013e3180582439","article-title":"The effectiveness of intramuscular biperiden in acute akathisia: a double-blind, randomized, placebo-controlled study","volume":"27","author":"Baskak","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R55-9-20210206","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.4088\/JCP.v68n1124e","article-title":"A case of aripiprazole-related tardive akathisia and its treatment with ropinirole","volume":"68","author":"Hettema","year":"2007","journal-title":"J Clin Psychiatry"}],"container-title":["Current Opinion in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/YCO.0b013e32832a16da","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:53:48Z","timestamp":1786038828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001504-200905000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/yco.0b013e32832a16da","relation":{},"ISSN":["0951-7367"],"issn-type":[{"value":"0951-7367","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}